Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$28.63M$28.63M−47.6% vs Q2 2021 Net Income-$67.03M-$67.03MN/M vs Q2 2021 EPS Diluted-$1.05-$1.05N/M vs Q2 2021 Operating Income-$78,526,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$36,823,000N/M Margins · derivedOperating margin-274.2%−209.6 pt vs Q2 2021
Net margin-234.1%−162.7 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end